Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatitis d.
Koytak ES, Yurdaydin C, Glenn JS. Koytak ES, et al. Among authors: yurdaydin c. Curr Treat Options Gastroenterol. 2007 Dec;10(6):456-63. doi: 10.1007/s11938-007-0045-8. Curr Treat Options Gastroenterol. 2007. PMID: 18221606
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.
Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; Hepatitis Delta International Network (HDIN). Yurdaydin C, et al. J Hepatol. 2019 May;70(5):1008-1015. doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27. J Hepatol. 2019. PMID: 30982526 Review.
Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta.
Wranke A, Hardtke S, Heidrich B, Dalekos G, Yalçin K, Tabak F, Gürel S, Çakaloğlu Y, Akarca US, Lammert F, Häussinger D, Müller T, Wöbse M, Manns MP, Idilman R, Cornberg M, Wedemeyer H, Yurdaydin C. Wranke A, et al. Among authors: yurdaydin c. J Viral Hepat. 2020 Dec;27(12):1359-1368. doi: 10.1111/jvh.13366. Epub 2020 Aug 11. J Viral Hepat. 2020. PMID: 32707605 Clinical Trial.
Cytotoxic CD4 T cells in viral hepatitis.
Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, Meyer MF, Heiken H, Kuhlmann B, Kaiser T, Bozkaya H, Tillmann HL, Bozdayi AM, Manns MP, Wedemeyer H. Aslan N, et al. Among authors: yurdaydin c. J Viral Hepat. 2006 Aug;13(8):505-14. doi: 10.1111/j.1365-2893.2006.00723.x. J Viral Hepat. 2006. PMID: 16901280
Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection.
Mederacke I, Yurdaydin C, Großhennig A, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Chatzikyrkou C, Bozkaya H, Dalekos GN, Manns MP, Wedemeyer H; Hep-Net/International Delta Hepatitis Study Group. Mederacke I, et al. Among authors: yurdaydin c. J Viral Hepat. 2012 Jun;19(6):387-95. doi: 10.1111/j.1365-2893.2011.01560.x. Epub 2011 Dec 19. J Viral Hepat. 2012. PMID: 22571900 Clinical Trial.
Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN).
Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, Dalekos GN, Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P, Vanwolleghem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C, Manns MP, Wedemeyer H, Hardtke S; Hepatitis Delta International Network. Wranke A, et al. Among authors: yurdaydin c. Liver Int. 2018 May;38(5):842-850. doi: 10.1111/liv.13604. Epub 2017 Oct 26. Liver Int. 2018. PMID: 28963781
A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
Anastasiou OE, Yurdaydin C, Maasoumy B, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Radu M, Liebig S, Bantel H, Bremer B, Manns MP, Cornberg M, Wedemeyer H. Anastasiou OE, et al. Among authors: yurdaydin c. J Viral Hepat. 2021 Feb;28(2):410-419. doi: 10.1111/jvh.13439. Epub 2020 Dec 12. J Viral Hepat. 2021. PMID: 33185325 Clinical Trial.
188 results